Transcriptional and Post-transcriptional Mechanisms of BAFF-receptor Dysregulation in Human B Lineage Malignancies
Overview
Affiliations
Together, circulating BAFF and dominant receptor BAFF-R homeostatically regulate the humoral immune system. Consistently aberrant BAFF-R expression in leukemic cells reveals an intimate connection of these cells' malignant physiology to the BAFF/BAFF-R axis and also provides an additional survival mechanism to the expressing cells. In this study, we used primary cells and cell lines to interrogate the mechanisms underlying aberrant BAFF-R expression in precursor B acute lymphoblastic leukemia (precursor B-ALL) and mature B chronic lymphocytic leukemia (CLL). Here we demonstrate the aberrant expression of BAFF-R in precursor B-ALL cell lines and reveal that these cells acquire BAFF-R expression through premature transcriptional activation of the BAFF-R promoter in coordination with regulatory transcription factor c-Rel. Investigations using primary CLL cells provide a crucial counterpoint through their paucity of BAFF-R relative to their benign mature B cell counterparts, which we establish as functionally significant in its depletion of the CLL cells' BAFF-binding capacity. Furthermore, BAFF-R downregulation in CLL patients is revealed here to be restricted to the malignant compartment and mediated post-transcriptionally in order to compensate for the consistently unchanged levels of transcription factor c-Rel and BAFF-R mRNA. Finally, we present evidence that CLL cells retain endogenous mechanisms of BAFF-R regulatory control despite active receptor dysregulation.
Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells.
Qie Y, Gadd M, Shao Q, To T, Liu A, Li S MedComm (2020). 2024; 5(9):e716.
PMID: 39224539 PMC: 11366826. DOI: 10.1002/mco2.716.
Clar K, Weber L, Schmied B, Heitmann J, Marconato M, Tandler C Cancers (Basel). 2021; 13(23).
PMID: 34885231 PMC: 8657109. DOI: 10.3390/cancers13236122.
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.
Li G, Zhang Q, Liu Z, Shen H, Zhu Y, Zhou Z Cancer Cell Int. 2021; 21(1):223.
PMID: 33865370 PMC: 8052726. DOI: 10.1186/s12935-021-01923-x.
BAFF/APRIL System Is Functional in B-Cell Acute Lymphoblastic Leukemia in a Disease Subtype Manner.
Sevdali E, Katsantoni E, Smulski C, Moschovi M, Palassopoulou M, Kolokotsa E Front Oncol. 2019; 9:594.
PMID: 31380267 PMC: 6657364. DOI: 10.3389/fonc.2019.00594.
Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.
Vicioso Y, Gram H, Beck R, Asthana A, Zhang K, Wong D Cancer Immunol Res. 2019; 7(7):1106-1119.
PMID: 31138521 PMC: 6606383. DOI: 10.1158/2326-6066.CIR-19-0058.